The MDMA-Assisted Therapy Market is expected to grow on an irreversible note in the next 10 years. The future scenario would be data-driven healthcare. This would, in turn, widen the potential for enhancing treatment options. With interoperability taking the centre stage, program participants could access app blueprints, data templates, and security tools. Thus, the big data cloud would turn out to be kinetic. This would result in an upswing in the healthcare vertical going forward.
According to the latest research by Persistence Market Research, the MDMA-assisted therapy market is set to witness positive growth of CAGR 3.4% during 2021-2031. MDMA (3-4 methylenedioxymethamphetamine) is a drug that can be used in posttraumatic stress disorder (PTSD), the anxiety caused due to end-stage diseases like cancer.
PTSD can occur after any traumatic event or can occur with depression and anxiety. The MDMA- assisted therapy market is mainly driven by the increase in the prevalence of PTSD, anxiety, new products in the pipeline and government initiatives for treatment of PTSD. The companies are exploring treatment options for PTSD with the help of derivatives of MDMA and different combinations.
MDMA- assisted therapy includes treatment of posttraumatic stress disorder, anxiety related to end-stage diseases like cancer, social anxiety in autistic patients, etc. According to the national centre for PTSD, about 6% of the population will have PTSD at some point in their lives. Also, in the U.S. during a given year about 15 million people suffer from PTSD. This increasing prevalence of PTSD will drive the market in the forecasted period.
To remain ‘ahead’ of your competitors, request for a sample@ https://www.persistencemarketresearch.com/samples/32977
The initiatives taken by the government for the awareness of anxiety and post-trauma stress will drive the market. For instance, the U.S. is the helpline centre for veterans who are diagnosed with PTSD or suffer from the same. In addition, the firms are working on clinical trials for using MDMA as a medication to treat PTSD.
Moreover, an increase in the awareness about MDMA-assisted therapy and R & D investment by the companies for developing new products is expected to increase demand for MDMA-assisted therapy during the forecast period.
Currently, there are no FDA approved MDMA drugs available in the market. However, the companies are involved in clinical trials for the treatment of post-traumatic stress disorder (PTSD), anxiety related to cancer, depression etc. For instance, in 2019, Atai Life Sciences and Bionomics partnered together for exploring the combination treatment regimen.
Get A Customized Scope To Match Your Need Ask An Expert – sales@persistencemarketresearch.com
This combination included EmpathBio’s MDMA derivative, EMP-01, and Bionomics’ lead drug candidate, BNC210. Apart from this, in June 2021, Awakn Life Sciences Corp. has filed a patent application for its MDMA-derived new chemical entities, AWKN001 and AWKN002 for the treatment of a broad range of addictions.
The MDMA –assisted therapy market is mainly dominated by North America with countries like the US and Canada is dominating the MDMA-assisted therapy market. This is due to the presence of major players like Awakn Life Sciences and the government initiatives to spread awareness about post-trauma stress.
Another region that is expected to dominate the market is Europe followed by Asia. This is because PTSD is common in this area. According to a study published in Oxford Medicine, PTSD affects approximately 1% to 3% of the European population every year.
Pre-Book Right Now for Exclusive Analyst Support@ https://www.persistencemarketresearch.com/checkout/32977
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
